{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:50Z","timestamp":1761171890642,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":3520,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.farma.2011.03.008","type":"journal-article","created":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T04:21:44Z","timestamp":1347596504000},"page":"321-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efecto del seguimiento farmacoterap\u00e9utico en pacientes con hiperparatiroidismo secundario tratados con cinacalcet"],"prefix":"10.1016","volume":"36","author":[{"given":"C.","family":"Chemello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Calleja-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Faus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2011.03.008_bib0005","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"year":"2005","series-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Dipiro","key":"10.1016\/j.farma.2011.03.008_bib0010"},{"key":"10.1016\/j.farma.2011.03.008_bib0015","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1016\/j.transproceed.2006.10.133","article-title":"Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet","volume":"38","author":"Apostolou","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.farma.2011.03.008_bib0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ncpneph0191","article-title":"Drug insight: renal indications of calcimimetics","volume":"2","author":"Shahapuni","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.farma.2011.03.008_bib0025","unstructured":"Ficha t\u00e9cnica Cinacalcet [consultado Jun 2010]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR__Product_Information\/human\/000570\/WC500028900.pdf."},{"key":"10.1016\/j.farma.2011.03.008_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a New Cinacalcet (Sensipar\/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.farma.2011.03.008_bib0035","unstructured":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [consultado Mar 2008]. Disponible en: http:\/\/www.kidney.org\/professionals\/kdoqi\/guidelines_bone\/index.htm"},{"key":"10.1016\/j.farma.2011.03.008_bib0040","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI TM bone metabolism and disease treatment goals with Cinacalcet HCL","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.farma.2011.03.008_bib0045","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.farma.2011.03.008_bib0050","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/01.tp.0000253429.33198.2f","article-title":"Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation","volume":"83","author":"El-Amm","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.farma.2011.03.008_bib0055","first-page":"533","article-title":"Oportunities and responsabilities in the pharmaceutical care","volume":"47","author":"Hepler","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.farma.2011.03.008_bib0060","first-page":"5","article-title":"Third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM)","volume":"48","year":"2007","journal-title":"Ars Pharmaceutical"},{"key":"10.1016\/j.farma.2011.03.008_bib0065","first-page":"792","article-title":"Drug-related hospital admissions","volume":"33","author":"McKenney","year":"2006","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.farma.2011.03.008_bib0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-006-0116-0","article-title":"Medicine-related problems resulting in emergency department visits","volume":"62","author":"Baena","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.03.008_bib0075","unstructured":"Grabe DW. Drug-related problems in the end-stage renal disease population. Medscape Pharmacists. 2000 [consultado Mar 2009]. Disponible en: www.medscape.com\/viewarticle\/408570"},{"key":"10.1016\/j.farma.2011.03.008_bib0080","unstructured":"Consenso sobre Atenci\u00f3n Farmac\u00e9utica. Madrid: Ministerio de Sanidad y Consumo; 2002."},{"key":"10.1016\/j.farma.2011.03.008_bib0085","unstructured":"Ley 28\/2009, de 30 de diciembre, de modificaci\u00f3n de la Ley 29\/2006, de 26 de julio, de garant\u00edas y uso racional de los medicamentos y productos sanitarios. Madrid, Espa\u00f1a. BOE n\u00fam. 315, de 31 de diciembre."},{"key":"10.1016\/j.farma.2011.03.008_bib0090","unstructured":"U.S. Pharmacist. Postgraduate Healthcare Education. The Role of the Pharmacist in the Identification and Management of Secondary Hyperparathyroidism [consultado Mar 2008]. Disponible en: http:\/\/www.uspharmacist.com\/oldformat.asp?url=ce\/105514\/default.htm"},{"key":"10.1016\/j.farma.2011.03.008_bib0095","first-page":"309","article-title":"Dader Method to provide pharmacotherapy follow-up","volume":"46","year":"2005","journal-title":"Ars Pharm"},{"key":"10.1016\/j.farma.2011.03.008_bib0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.farma.2011.03.008_bib0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEMMA study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.farma.2011.03.008_bib0110","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archinternmed.2009.59","article-title":"Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease","volume":"169","author":"Murray","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.farma.2011.03.008_bib0115","first-page":"989","article-title":"Impact of Pharmaceutical Care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeir\u00e3o Preto (SP)","volume":"3","author":"de Lyra","year":"2007","journal-title":"Brazil Ther Clin Risk Manag"},{"key":"10.1016\/j.farma.2011.03.008_bib0120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.1238","article-title":"Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRP)","volume":"15","author":"Viktil","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.farma.2011.03.008_bib0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/193229680900300313","article-title":"Can technology improve adherence to long-term therapies?","volume":"3","author":"Reach","year":"2009","journal-title":"J Diabetes Sci Technol"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2011.03.008_bib0130","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0895-4356(01)00457-7","article-title":"Treatment adherence in chronic disease","volume":"54","author":"Dunbar-Jacob","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.farma.2011.03.008_bib0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfl560","article-title":"Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients","volume":"22","author":"Serra","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.farma.2011.03.008_bib0140","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfl840","article-title":"Implementation of \u2018K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease\u2019 after the introduction of cinacalcet in a population of patients on chronic haemodialysis","volume":"22","author":"Arenas","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.farma.2011.03.008_bib0145","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study","volume":"24","author":"Ure\u00f1a","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 113","key":"10.1016\/j.farma.2011.03.008_bib0150","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311002108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311002108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:34Z","timestamp":1761106654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634311002108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1130634311002108"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2011.03.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efecto del seguimiento farmacoterap\u00e9utico en pacientes con hiperparatiroidismo secundario tratados con cinacalcet","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2011.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEFH. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}